Cobi Bio Co., Ltd., a resident company of the Daegu-Gyeongbuk Advanced Medical Complex, announced on December 2 that after continuous research and development efforts and attempts at business diversification, it has recently launched a traditional Korean herbal throat candy called "Heuksam Gamgildan," which utilizes black ginseng.
"Heuksam Gamgildan" is a product developed by combining a manufacturing technology for black ginseng extract (containing Rk1 and Rg5) and the traditional Korean medicine prescription technique of Gamgiltang, based on preclinical studies showing that black ginseng has a significant effect in suppressing chronic obstructive pulmonary disease (COPD).
This product is effective for chronic sore throat, cough, and asthma, and is made in a candy form so that even children can easily carry and consume it.
Cobi Bio Co., Ltd. (CEO Lee Panje) is the only company in the complex specializing in research and development related to traditional Korean medicine, having moved into the Daegu Sinseo-dong Advanced Medical Complex upon its establishment in 2017.
Cobi Bio is a bio startup focused on research and development of functional products using herbal natural substances, aiming to modernize and scientifically advance traditional Korean medicine while enhancing user convenience and functionality.
CEO Lee Panje is a doctor of traditional Korean medicine who has operated a clinic for over 30 years, pursuing the scientific advancement and standardization of Korean medicine by integrating the therapeutic principles and accumulated clinical experience of traditional medicine with the objective verification methods of Western medicine.
In 2018, Cobi Bio developed the "Jawoongo Package," a topical herbal treatment for skin diseases, through the "SME Joint Research Center Resident Company Support Project," funded by Daegu City and operated by K-MEDI HUB.
Jawoongo is one of the most widely used ointments in traditional Korean medicine for wound healing, trouble improvement, and moisturizing. The introduction of a disposable container design has enhanced both safety and functionality.
Additionally, with the support of K-MEDI HUB researchers, the company developed home care herbal treatment products for nasal diseases, including "Tongbi7" for pus drainage, various nasal topical agents, and products effective in relieving nasal mucosal inflammation and alleviating rhinitis.
The herbal topical agents developed by Cobi Bio are currently being supplied through over 100 joint decoction contracts via Cobi One External Decoction, a manufacturer specializing in traditional herbal medicines. They are currently exported to Canada and Australia, with plans to expand into Southeast Asia and Japan in the future.
Cobi Bio is preparing for business expansion by not only developing its own core technologies but also building a specialized production facility infrastructure of about 3,300 square meters for manufacturing and quality control.
Yang Jinyoung, Chairman of K-MEDI HUB, stated, "I am pleased and find it meaningful that K-MEDI HUB's support has served as a foundation for corporate growth. I hope you will open up new possibilities for Korean medicine through the harmony of traditional and modern medicine, and I look forward to further development through exchanges and cooperation with related organizations such as the National Institute for Korean Medicine Development and Daegu Haany University Korean Medicine Hospital, which are also located within the complex."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
